Press
Releases

November 13, 2025 Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update November 8, 2025 Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025 November 3, 2025 Jade Biosciences to Participate in Upcoming Conferences October 17, 2025 Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025 October 7, 2025 Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases October 7, 2025 Jade Biosciences Announces $135 Million Private Placement September 2, 2025 Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy August 25, 2025 Jade Biosciences to Participate in Upcoming Conferences August 13, 2025 Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update July 8, 2025 Jade Biosciences to Participate in Two Upcoming Investor Conferences